Where does Amylyx Pharmaceuticals, Inc.'s cash flow data come from?

Every line is extracted from Amylyx Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Net income	-$150.11M+31.4%	-$144.74M+52.0%	-$149.28M+42.5%	-$187.6M-13.1%	-$218.86M-208%
Depreciation and amortization	$467K-37.3%	$525K-41.9%	$577K-44.8%	$678K-39.8%	$745K-37.9%
Stock-based compensation	$26.93M-10.1%	$27.65M-16.3%	$28M-21.9%	$27.73M-29.3%	$29.95M-24.3%
Net cash from operating activities	-$120.4M+41.8%	-$123.34M+26.4%	-$154.45M-62.4%	-$165.65M-182%	-$206.98M-1,354%
Capital expenditures	——	$138K—	$72K—	——	——
Net cash from investing activities	——	——	——	——	$31.18M—
Proceeds from issuance of debt	——	——	——	——	——
Net cash from financing activities	——	——	——	——	$65.88M+2,401%
Net increase (decrease) in cash	$168.91M+246%	$148.8M+252%	$147.32M+335%	-$21.74M—	-$115.62M—

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Amylyx Pharmaceuticals, Inc.'s cash flow data come from?: Every line is extracted from Amylyx Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.